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Different Brain Regions are 
Infected with Fungi in Alzheimer’s 
Disease
Diana Pisa1, Ruth Alonso1, Alberto Rábano2, Izaskun Rodal2 & Luis Carrasco1
The possibility that Alzheimer’s disease (AD) has a microbial aetiology has been proposed by 
several researchers. Here, we provide evidence that tissue from the central nervous system (CNS) 
of AD patients contain fungal cells and hyphae. Fungal material can be detected both intra- and 
extracellularly using specific antibodies against several fungi. Different brain regions including 
external frontal cortex, cerebellar hemisphere, entorhinal cortex/hippocampus and choroid plexus 
contain fungal material, which is absent in brain tissue from control individuals. Analysis of brain 
sections from ten additional AD patients reveals that all are infected with fungi. Fungal infection 
is also observed in blood vessels, which may explain the vascular pathology frequently detected in 
AD patients. Sequencing of fungal DNA extracted from frozen CNS samples identifies several fungal 
species. Collectively, our findings provide compelling evidence for the existence of fungal infection in 
the CNS from AD patients, but not in control individuals.
Neurodegenerative diseases constitute a heterogeneous group of disorders of the central nervous system 
(CNS) that are characterised by a slow and irreversible loss of neuronal functions. The aetiology of pri-
mary neurodegenerative diseases, such as Alzheimer’s disease (AD), multiple sclerosis (MS), Parkinson’s 
disease (PD) and amyotrophic lateral sclerosis (ALS), remains largely unknown. A common feature 
of many neurodegenerative diseases is the presence of aggregates of misfolded proteins (intracellular 
inclusions) in regions of the CNS that can serve as neuropathological hallmarks for disease diagnosis1,2. 
Depending on the particular disease, these insoluble fibrillar aggregates can vary in distribution and 
composition3. Histopathologically, AD is characterised by the accumulation of intracellular tangles of 
hyperphosphorylated tau protein and extracellular deposits of amyloid protein4,5. Proteolytic process-
ing of membrane-associated amyloid precursor protein (APP) results in the generation of neurotoxic 
amyloid β (Aβ ) peptide6,7, which is the major component of the distinctive senile plaques in AD. The 
cytotoxicity induced by Aβ pepetide involves disruption of calcium homeostasis, oxidative stress, syn-
aptic dysfunction and neuronal loss8–10. The prevailing dogma to explain the pathogenesis of AD is that 
the accumulation of amyloid deposits formed by Aβ pepetide may induce intracellular tangles of tau 
protein that in turn leads to neuronal death11. However, the so-called “amyloid hypothesis” has been 
questioned by several findings including the failure of clinical trials aimed to lower amyloid depos-
its or tau tangles12–14. Moreover, many elderly people with normal cognitive function have substantial 
amyloid burden in their CNS11. At present, there is no therapy to stop or reverse the symptoms of AD. 
Aside from cognitive decline, the vast majority of AD patients present clear signs of inflammation and 
damage to blood vessels15,16. Inflammation of the CNS and immune activation play a major role in the 
pathophysiology of AD. Indeed, a number of cytokines, such as interleukins (IL-1 and IL-6), tumor 
necrosis factor α and interferon γ , are elevated in the brain of AD patients, suggesting an increased 
immune response17–19. These observations have led to the speculation that AD has an autoimmune aeti-
ology20. Many investigators have also considered the idea that AD is an infectious disease, or at least that 
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infectious agents constitute a risk factor for AD21–23. Accordingly, genetic material from several viruses 
and bacteria have been reported in brains from AD patients. In particular, herpes simplex type 1 (HSV-1) 
and Chlamydophila pneumoniae have been suggested as potential aetiological agents of AD. In addition, 
brain infection by several pathogens may induce amyloid formation24–26. Furthermore, Α β peptide exhib-
its antimicrobial activity and shows particularly strong inhibitory activity against Candida albicans27.
Recently, we provided strong evidence for fungal infection in AD patients28,29. Fungal DNA and pro-
teins were found in frozen brain tissue from AD patients, but not from control patient tissue. Moreover, 
fungal material could be detected intra- and extracellularly in neurons from AD patients. In the present 
work, we have examined in detail the presence of fungal structures in different regions of the brain 
of an AD patient by immunohistochemistry. No fungal material was observed in brain tissue from 
ten control individuals, whereas fungal infection was clearly present in brains from ten additional AD 
patients. Moreover we were able to amplify fungal DNA from frozen tissue of different AD brain regions. 
Collectively, our findings provide compelling evidence for the presence of fungal infection in brains from 
all AD patients analysed.
Results
Fungal structures in AD CNS. One of the most direct approaches to detect fungal infection in the 
CNS is the visualisation of fungi in tissue sections. It is well established that the hierarchical pattern 
of neurofibrillary degeneration and thus the early pathological lessions in AD patients generally starts 
by modifications in the entorhinal cortex, followed by the hippocampus, association cortex and finally 
the primary neocortex11. We first analysed fixed sections from different regions of the CNS from one 
AD patient (AD1) and a control individual (C1) (Supplementary Table I). The regions examined were 
external frontal cortex (EFC), cerebellar hemisphere (CEH), entorhinal cortex/hippocampus (ERH) and 
choroid plexus (CP). Notably, fungal cells were detected in the four regions examined from patient AD1 
as demonstrated by immunohistochemistry and confocal microscopy using anti-C. glabrata antibodies 
(Fig. 1). In some instances, fungal cells were clearly visible inside neurons and exhibited an intranuclear 
location as indicated by counterstaining with the DNA stain, 4'6-diamidino-2-phenylindole (DAPI). The 
size of the fungal bodies was variable; in some instances, the size was 1–2 μ m, whereas the diameter 
of other fungal bodies was greater (approximately 5–10 μ m). In other instances, smaller fungal bodies 
of 0.4–1 μ m were evident depending on the field analysed. The 0.4–1 and the 1–2 μ m-sized bodies are 
similar to those previously reported for some intracellular yeast cells30–32. These intracellular forms are 
known as endomycosomes29,33. Endothelial cells in the CP may also contain fungal bodies. No fungal 
cells or fungal material were apparent in the different CNS regions from the control (C1) individual 
(Fig. 1). Curiously, immunostaining of tau protein with specific antibodies localised tau not only in the 
cytoplasm, but also in the nucleus in both AD1 and C1 sections. This finding is consistent with the obser-
vation that nuclear pores are damaged in elderly people, particularly with neurodegenerative diseases, 
and cytoplasmic proteins can relocate to the nucleus34,35. Nuclear tau protein staining was very strong in 
neurons where intranuclear fungal bodies were detected.
Wider fields illustrating the presence of additional fungal bodies and a more general view of the 
fungal infection are shown in Supplementary Figures 1, 2 and 3. Nuclear (DAPI) staining (blue) and 
double immunofluorescence staining to detect fungal structures (green) and tau protein (red) was carried 
out and only the merged panel is shown for space restrictions. Several fungal morphologies could be 
observed in the EFC, with sizes ranging from 0.4–1 and 5–10 μ m. The sizes of the fungal bodies found 
in the CEH were approximately 1–2 μ m. Strikingly, two different fields of the ERH revealed amylaceous 
bodies (corpora amylacea), which were prominently stained in the border of these rounded structures. 
However, immunostaining was not evenly distributed in all the border zones, indicating that the fungal 
material is not distributed homogeneously. Collectively, these observations demonstrate the presence 
of fungal material in different CNS regions examined, but only in the AD patient (AD1). The fungal 
structures could be detected outside and inside nuclei and, in some instances, fungal cells were positive 
for DAPI, indicating that they contain nucleic acids (see upper-right panel in Supplementary Figure 1).
Detection of fungal cells and hyphae using different anti-fungal antibodies. It must be kept 
in mind that the immunoreactivity observed with anti-C. glabrata antibodies does not necessarily mean 
that this yeast is present. Because the antibodies employed are rabbit polyclonal, they can crossreact with 
a number of proteins from other fungi. The spectrum of proteins recognised by the different anti-fungal 
antibodies employed in this work vary and depend on the fungal species present in each case. However, 
these anti-fungal antibodies do not crossreact with cellular proteins from control individuals. To further 
assess whether fungal cells were present in patient AD1, we carried out immunohistochemistry analysis 
using rabbit polyclonal antibodies raised against other fungi. Four additional antibodies (raised against 
C. famata, C. albicans. P. betae, and S. racemosum) detected fungal components (green) in the tissue 
sections analysed (Fig. 2), as demonstrated by double staining with an anti-neurofilament antibody (red). 
As indicated previously, the size of the fungal cells detected with the antibodies varied. The additional 
antibodies also detected long fibrilar structures clearly resembling fungal hyphae, with sizes ranging 
from 0.1 μ m to 1–2 μ m. The variety of sizes and morphologies observed in these sections using different 
anti-fungal antibodies is consistent with the notion that several fungal species were present in the three 
CNS regions examined. Analyses of tissue sections from C1 using these antibodies failed to reveal any 
www.nature.com/scientificreports/
3Scientific RepoRts | 5:15015 | DOi: 10.1038/srep15015
Figure 1. Immunohistochemistry analysis of tissue sections from different regions of the CNS using 
anti-C. glabrata antibodies. CNS sections from patient AD1 and control individual C1 were obtained 
from fixed tissue and immunohistochemistry analysis by confocal microscopy was carried out as detailed in 
Materials and Methods. EFC: external frontal cortex; CEH: cerebellar hippocampus; ERH: entorhinal cortex/
hippocampus; CP: choroid plexus. DAPI appears in blue, anti-C. glabrata is shown in green and TauT100 in 
red. The different panels in the figure are indicated. Scale bar: 5 μ m.
www.nature.com/scientificreports/
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fungal material (results not shown). The possibility that these antibodies recognise human proteins pres-
ent only in CNS samples from patient AD1 and form structures that resemble different fungal morpholo-
gies is unlikely. To further test the presence of fungal proteins in patient AD1, we extracted proteins from 
different CNS regions of AD1 and C1 and performed western blotting with anti-C. albicans antibodies 
(Supplementary Figure 4). No specific protein bands were detected by this technique, most probably due 
to the fact that the amount of fungal proteins is extremely low. To unequivocally identify fungal proteins 
in brain tissue from AD patients, proteomic methodologies are required as we have previously reported28. 
Using this approach, we have detected several fungal proteins that are present in CNS samples from AD 
patients, but not in control individuals.
In accord with the earlier finding, some fungal cells and hyphae stained positive for DAPI (blue), sug-
gesting that they contain nucleic acids (Fig. 2). In EFC sections stained with anti-C. famata and anti-S. 
Figure 2. Immunohistochemistry analysis of CNS sections from patient AD1 using different anti-fungal 
antibodies. Immunohistochemistry analysis of different CNS sections from patient AD1 was carried out 
as indicated in Fig. 1. EFC: external frontal cortex; CEH: cerebellar hippocampus; ERH: entorhinal cortex/
hippocampus. DAPI appears in blue, anti-C. famata, anti-C. albicans, anti-P. betae and anti-S. racemosum are 
shown in green and human neurofilament in red. The different panels in the figure are indicated. Scale bar: 
10 μ m.
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racemosum antibodies, DAPI staining was clearly located inside hyphae. Indeed, DAPI positivity could 
be seen in the vast majority of cells and hyphae after longer exposure times, but under these conditions 
neuron nuclei were overexposed. To overcome this limitation, the blue DAPI staining was converted 
to magenta and the antifungal antibody staining was in green. Under these conditions, positive DAPI 
staining was observed in all the morphologies found, i.e. yeast-shaped cells and hyphae (Fig. 3), and this 
was also the case when the anti-C. glabrata antibodies were employed (Fig. 1).
Because most of the above results were obtained from only one AD patient and one control individ-
ual, it was of interest to examine CNS sections from additional AD patients and controls. To this end, 
we analysed ERH tissue sections from a further ten AD patients and ten controls by double immunos-
taining with anti-fungal (green) and anti-tubulin (red) antibodies. Notably, fungal infection was evident 
in all AD patients studied (Fig. 4), whereas no fungal cells were detected in tissue sections from control 
individuals (Supplementary Figure 5). The morphology of the fungal structures detected in the additional 
AD patients was similar to that described for AD1, although not all structures were found in all patients. 
Moreover, some of these structures were very striking; for example, conidial structures were observed in 
patients AD2 (anti-C. glabrata) and AD8 (anti-C. albicans), and hyphae formation was observed from 
a fungal cell in patient AD6 (anti-C. albicans). The small hyphae and yeast cells found in patient AD5 
(anti-Phoma staining) was very striking. The existence of different fungal morphologies reinforces the 
idea that several species can be present, supporting the concept of mixed fungal infections. In conclu-
sion, fungal cells and/or hyphae were found in all AD patients analysed although the morphological 
characteristics may be different for each patient, thus implying that the fungal species present in each 
patient may also differ.
Fungal infection of the neurovascular system. The majority of AD patients exhibit pathological 
lesions of the vascular system in the CNS16,36. Up to 90% of AD patients present various cerebrovas-
cular pathologies, including cerebral amyloid angiopathy, microinfarcts, haemorrhages and microvas-
cular degeneration. Accordingly, deposits of amyloid β in the walls of capillaries, small arterioles and 
medium-size arteries are evident in most AD patients studied. These amyloid deposits give rise to cere-
bral amyloid angiopathy. We reasoned that if fungal infection is present in blood vessels, it might induce 
the formation of amyloid deposits and angiopathy. To assess fungal infection in blood vessels from EFC, 
ERH and CP regions, we carried out confocal immunofluorescence analysis. Fungal cells of different sizes 
and hyphae were detected inside capillaries and other blood vessels (Fig. 5). Some staining was also evi-
dent in the vessel walls, demonstrating that fungal infection can be detected in the neurovascular system. 
Also, the CP region from patient AD1 (Fig.  5), but not from C1 (Supplementary Figure 6), contained 
fungal cells and hyphae that immunoreacted with the different anti-fungal antibodies. These results are in 
good agreement with the notion that several fungal species can infect blood vessels and cause pathologi-
cal modifications37–39. These studies were extended to the analysis of the CP region from three additional 
AD patients (AD12, 13, 14) using several anti-fungal antibodies., Consistent with the previous result, 
fungal material was detected in all three cases examined, but not in the control (Supplementary Figure 6). 
In conclusion, fungal structures can be observed also in the vascular system of AD patients.
Identification of fungal species in the different CNS regions. DNA amplification and sequencing 
is the most precise approach to determine specific fungal species present in CNS tissues. Because the 
vast majority of DNA from tissue samples is human, we previously developed a sensitive nested PCR 
assay to amplify fungal DNA present in very minor amounts28,33,40,41. We recently used this tecnhnique 
successfully to identify several fungal species in brain samples from AD patients40. To identify the fungal 
species present in the different brain regions of patient AD1, we extracted DNA from frozen tissue and 
performed PCR using primers that amplify two internal transcribed spacers (ITS-1 and ITS-2) located 
between ribosomal RNA genes (see scheme, Supplementary Figure 7). Several different PCR assays were 
carried out since in our experience the use of several primer pairs ensures the amplification of DNA from 
different fungal species. We first amplified ITS-1 with primers ITS-1 (external) and then three different 
PCR assays were subsequently performed with internal primer pairs (ITS-1, internal). In addition, ITS-2 
was first amplified with primers ITS-2 (external) followed by a second PCR with an ITS-2 (internal) 
primer pair. DNA amplified by each PCR was separated on agarose gels and we sequenced the extracted 
fragments. A typical PCR result after amplification of the ITS-1 using DNA extracted from the different 
CNS regions of patient AD1 and C1 is shown in Supplementary Figure 7. No PCR products were ampli-
fied from DNA extracted from the different regions of C1, or from controls for DNA extraction and PCR. 
These findings reveal that no fungal contamination occurred in the PCR assay or during DNA extraction. 
Sequencing of each fragment from the four PCR assays using DNA from patient AD1 revealed a number 
of fungal species as listed in Table 1. Of note, several species could be detected from the same region, 
supporting the concept of mixed fungal infection. Conversely, no single fungal species was present in all 
four regions of the CNS examined. Of note, some of the species detected, such as Malasezzia spp., Phoma 
and S. cerevisiae, have been previously identified in AD brains40. Significantly, the majority of the species 
listed in Table 1 are described as human pathogens42,43. The possibility that different fungal species or a 
combination of species serves as a risk factor or represents the cause of AD might explain the diversity 
observed in the evolution and severity of clinical symptoms in each AD patient.
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Figure 3. DAPI staining of nuclei of the different fungal morphologies. DAPI staining is shown in 
magenta to visualize more clearly the fungal nuclei. Immunoreactivity with the fungal antibodies indicated is 
shown in green. Panels A–G and S: anti-C. glabrata as primary antibody. Panels H–J, T, U, W: anti-C. famata 
as primary antibody. Panels: K–M, V, X: anti-C. albicans as primary antibody. Panels N, O, Y, Z: anti-S. 
racemosum. as primary antibody. Panels P-R: anti- P. betae as primary antibody. Panels K, L, S, T, U, Y: EFC 
of patient AD1. Panels A, H, M–Q, X: CEH of patient AD1. Panels I, J, R, V, W, Z: ERH of patient AD1. 
Panels B, C, D: CP of patient AD1. Panel E: ERH of patient AD3. Panel F: ERH of patient AD4. Panel G: 
ERH of patient AD9. Scale bar: 5 μ m is the same for all panels shown in the figure.
www.nature.com/scientificreports/
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Discussion
A major goal of AD research is to uncover the precise aetiology of the disease in order to implement 
adequate therapies to halt or even reverse clinical symptoms. The possibility that AD is a fungal disease, 
or that fungal infection is a risk factor for the disease, opens new perspectives for effective therapy for 
these patients. The present findings demonstrate that fungi can be detected in brain tissue from different 
regions of the AD CNS. In all eleven patients (plus three additional CP samples) described in this study, 
Figure 4. Immunohistochemistry analysis of entorhinal cortex sections from ten different AD patients. 
Entorhinal cortex sections from ten different AD patients were incubated with different antibodies (anti-C. 
glabrata, anti-C albicans and anti-P. betae) and are shown in green; human α -tubulin immunostaining is 
shown in red. Double immunofluorescence assay and confocal microscopy was carried out as indicated in 
Fig. 1 and Materials and Methods. DAPI appears in blue. Scale bar: 5 μ m.
www.nature.com/scientificreports/
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as well as in four patients previously analysed, there is clear evidence for fungal cells inside neurons or 
extracellularly29. Therefore, 100% of the AD patients analysed thus far by our laboratory present fungal 
cells and fungal material in brain sections. Moreover, fungal macromolecules (polysaccharides, proteins 
and DNA) have been found in blood serum from AD patients40 and fungal proteins and DNA were 
detected by proteomic analyses and PCR, repectively, from frozen tissue of AD brain28. Observations 
from other laboratories also support the possibility of fungal infections in AD patients. For example, chi-
tin bodies have been found in AD brains44,45. The proposal that chitin-like polysaccharides play a role in 
the amyloidogenic process and are aberrantly synthesised by neural cells has been suggested46; however, 
Figure 5. Fungal bodies in CNS blood vessels from patient AD1 detected by immunohistochemistry. 
Double immunofluorescence assay analyzed by confocal microscopy as described in Materials and Methods. 
Blood vessels from different CNS regions from patient AD1 are shown. Panels A–E: EFC. Panels F and G: 
ERH. Panels H–L: CP. Panels A and I: anti-C. famata as primary antibody. Panels B, C, J: anti-C. albicans as 
primary antibody. Panels D, G, K: anti-P. betae as primary antibody. Panels E and L: anti-S. racemosum as 
primary antibody. Panels F and H: anti-C. glabrata as primary antibody. Anti-fungal antibodies are shown 
in green. An anti-human neurofilament antibody was used in all panels, except panels F and H, which were 
stained with anti-TauT100 antibodies (red.) DAPI appears in blue. Scale bar: 10 μ m.
www.nature.com/scientificreports/
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since chitin is a component of the fungal cell wall, it seems possible that these chitin polysaccharides 
may originate from fungi. Supporting this notion, increased chitinase levels are found in blood serum 
and cerebrospinal fluid from AD patients47–50. Presumably, the presence of the substrate, i.e. fungal chi-
tin, induces the production of chitinase. Moreover, antifungal treatment in two patients diagnosed with 
AD reversed clinical symptoms51,52. The interpretation of these results was that perhaps these patients 
were misdiagnosed. Interestingly, Aβ peptide has potent antimicrobial activity, particularly against C. 
albicans27. Accordingly, it might be possible that the presence of a chronic fungal infection in AD CNS 
triggers the synthesis of Aβ peptide, which in turn leads to amyloid deposits. These reports together with 
our present findings support the notion that fungal infection may exist in AD.
Proceeding on the assumption that fungi are the aetiological agent of AD, all of the symptoms 
observed in AD patients can be readily explained. For example, the slow progression of the disease 
fits well with the chronic nature of fungal infections if they remain untreated. Moreover, inflammation 
and activation of the immune system may be due to an infectious fungal agent. Disseminated fungal 
infections can induce cytokine production53–55, which can take place years before the onset of cognitive 
decline as observed in AD. Thus, this disseminated infection may slowly spread to the CNS and synaptic 
dysfunction and neuronal loss takes place only when the fungal burden in some areas of the CNS is 
high. It is quite possible that the existence of one fungal infection may facilitate the colonisation by other 
fungal species that can affect other areas of the CNS, giving rise to mixed fungal infections. The diversity 
of fungal species that can affect the CNS, as well as the combinations of these species, may account for 
the observed differences in the evolution and severity of clinical symptoms found in AD patients. The 
pathology of the blood vessels observed in most AD patients can also be explained since they can be 
infected by fungi37–39, particularly arteries, where the oxygen content is higher. Finally, the genetic pre-
disposition observed in approximately 2–5% of AD patients can simply be due to their predisposition to 
acquire fungal infections because the genetic background of each individual is permissive for this56,57. To 
the best of our knowledge, none of the symptoms established in AD pathology seem incompatible with 
the concept that AD may be caused by fungi. Moreover, the dissapointing results obtained in human 
clinical trials designed to lower the burden of β -peptide or tau tangles does not support the amyloid cas-
cade hypothesis12–14. These findings suggest that the main pathological agent in AD is still unidentified.
The existence of fungal infection in AD patients may be due to its involvement in the aetiology of 
this disease, but it could also be possible that, for reasons yet unknown, these patients are more prone to 
this type of infection. The fact that they are elderly and may have a poor adaptive immune response, or 
possibly changes in the diet and hygiene habits, may contribute to the emergence of fungal infections. It 
is evident that clinical trials will be necessary to establish a causal effect of fungal infection in AD. There 
are at present a number of highly effective antifungal compounds with little toxicity58–61. A combined 
effort from the pharmaceutical industry and clinicians is needed to design clinical trials to test the pos-
sibility that AD is caused by fungal infection.
Materials and Methods
Description of patients and control individuals. In this study, we analysed both frozen and par-
affin-fixed samples of tissue obtained from brain donors diagnosed with AD and control individuals. 
Details about the age and gender of each patient are listed in Supplementary Table I. All samples were 
supplied by Banco de Tejidos, Fundación CIEN (Centro de Investigación de Enfermedades Neurológicas, 
Madrid. Spain). The ethics committee of Universidad Autónoma de Madrid approved the study. The 









Sacharomyces cerevisae 2; 3
Sclerotinia borealis 3 1;3
Table 1.  Fungal species present in frozen CNS samples from AD patients detected by PCR. EFC: 
External frontal cortex; CEH: Cerebellar hemisphere; ERH: Entorhinal cortexI/hippocampus; CP: Choroid 
plexus. The numbers in the Table indicate the PCR number which were positive for a given species. PCR 1: 
ITS-1 (external) + ITS-1 (internal 1). PCR 2: ITS-1 (external) + ITS-1 (internal 2). PCR 3: ITS-1 (external) 
+ ITS-1 (internal 3). PCR 4: ITS-2 (external) + ITS-2 (internal 1).
www.nature.com/scientificreports/
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transfer of samples was performed according to national regulations concerning research on human 
biological samples. For all cases, written informed consent is available. All ethico-legal documents of the 
brain bank, including written informed consent, have been approved by an ethics committee external to 
the bank. The donors were anonymous to the investigators who participated in the study.
Antifungal antibodies. Fungi were cultured as described29,33. After autoclaving and lyophilisa-
tion of fungal cells, rabbit antisera against Candida famata, C. albicans, C. glabrata, Phoma betae and 
Syncephalastrum racemosum were obtained by inoculation of 1 or 2 mg of dried fungi in 0.5 ml PBS, 
previously mixed with an equal volume of Freund’s adjuvant. Rabbits were inoculated up to three times 
every three weeks and the antibody titre and specificity of the sera were tested by immunohistochem-
istry and immunoblotting using fungal proteins. The protocols employed were approved by the ethics 
committee of Centro de Biologia Molecular “Severo Ochoa” (identification number: ES280790000180).
Immunohistochemistry analysis. Tissue sections from the CNS (5 μ m) were fixed in 10% buffered 
formalin for 24 h and then embedded in paraffin following standard protocols. For immunohistochemi-
cal analysis, paraffin was removed and tissues were rehydrated and boiled for 2 min in citrate buffer and 
then incubated for 10 min with 50 mM ammonium chloride. Subsequently, tissue sections were incubated 
for 10 min with PBS/Triton X-100 (0.1%) followed by 20 min with PBS/BSA (2%). Sections were incu-
bated overnight at 4 °C with a mouse monoclonal antibody raised against human α -tubulin (Sigma), 
human phospho-PHF-tau, clone AT100 (Thermo Scientific), or human neurofilament protein, clone 
2F11 (Dako), all at 1:50 dilution, or a rabbit polyclonal antibody raised against proteins obtained from 
C. glabrata, C. famata, C. albicans, P. betae and S. racemosum at 1:500 dilution. Thereafter, sections were 
washed with PBS and further incubated for 1 h at 37 °C with donkey anti-mouse IgG secondary antibody 
conjugated to Alexa 555 (Invitrogen) for α -tubulin, TT100 and neurofilament, and donkey anti-rabbit IgG 
secondary antibody conjugated to Alexa 488 (Invitrogen) at 1:500 dilution for C. glabrata, C. famata, 
C. albicans, P. betae and S. racemosum. Subsequently, tissue sections were stained with DAPI (Merck) 
and samples were treated with autofluorescence eliminator reagent (Merck). All images were collected 
and analysed with a LSM710 confocal laser scanning microscope combined with the upright micro-
scope stand AxioImager. M2 (Zeiss) running Zeiss ZEN 2010 software. The spectral system employed 
was Quasar + 2 PMTs. Images were deconvoluted using Huygens software (4.2.2 p0 Scientific Volume 
Imaging) and visualised with Fiji/Image J.
Analysis of proteins by western blotting. Protein extracts of EFC, CEH and ERH of AD1 and C1 
were collected in sample buffer, boiled for 5 min and resolved by SDS-PAGE. After electrophoresis, pro-
teins were transferred to a nitrocellulose membrane. Specific rabbit polyclonal antibodies raised against 
C. albicans were used at 1:1000 dilution. Anti-rabbit immunoglobulin G antibody coupled to peroxidase 
(Amersham) was used at a 1:5000 dilution. Protein bands were visualised with the ECL detection system 
(Amersham).
DNA Extraction from frozen CNS tissue. DNA was extracted from frozen samples of different 
CNS regions using the QIAmp (Qiagen) Genomic DNA Isolation Kit as follows: 20 μ l proteinase K 
(> 600 mAU/ml) and 180 μ l of buffer ATL were added to 25 mg of brain tissue, followed by pulse-vortexing 
for 15 s. Digestion was carried out at 56 °C for 1–3 h with agitation. Subsequently, 200 μ l of buffer AL was 
added to each sample followed by vortexing for 15 s and incubation at 70 °C for 10 min. A 200 μ l volume 
of ethanol was then added to each sample followed by vortexing for 15 s. The mixture was applied to the 
QIAamp Mini spin column and centrifuged at 8000 rpm for 1 min. Then, 500 μ l buffer AW was applied 
to the column followed by centrifugation at 8000 rpm for 1 min. After a final wash step with 500 μ l of 
buffer AW2 (14000 rpm for 3 min), samples were collected in 40 μ l distilled water and DNA was quanti-
fied in a NanoDrop® ND-1000 UV-Vis spectrophotometer. Negative controls included three samples of 
tri-distilled filtered water.
Design of oligonucleotides. For ITS oligonucleotides, the gene sequences of 5.8S, 18S and 28S 
rRNA as well as internal transcribed spacer regions (ITS-1 and ITS-2) from several organisms (C. albi-
cans, C. famata, C. parapsilosis, C. glabrata, Rhodotorula mucilaginosa, Pichia guilliermondii, Cryptococcus 
neoformans and Homo sapiens) were accessed via the GenBank database and were aligned using Clustal 
W sequence analysis package. Multiple potential primer-binding sites for primer pairs were chosen by 
comparing regions of Candida homologous with regions of the fungal group within the fungal kingdom 
with the most divergent DNA sequences and regions of Candida incongruous with the human DNA 
sequence. Primer selection was optimised for melting temperature equivalence, lack of duplex, hairpin, 
or primer-dimer formation, and internal stability using OLIGO software (Amplify).
Nested PCR. A number of measures were used to avoid PCR contamination including the 
use of separate rooms and glassware supplies for PCR set-up and products, aliquoted reagents, 
positive-displacement pipettes, aerosol-resistant tips and multiple negative controls. DNA samples 
obtained from frozen CNS tissue were analysed by nested PCR using several primer pairs. To amplify 
the ITS-1 region, the first PCR was carried out with 4 μ l of DNA incubated at 95 °C for 10 min followed 
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by 30 cycles of 45 s at 94 °C, 1 min at 57.3 °C and 45 s at 72 °C. Oligonucleotides used in the first PCR 
were forward ITS-1 (external 5′ ): 14485′GTTCTGGGCCGCACGGG 3′ 1465 and reverse ITS-1 (exter-
nal 3′ ): 106R5′ GGCAAAGATTCGATGATT3′88R. The second PCR was carried out using one of three 
primer sets. The second PCR was performed using 0.5 μ l of the product obtained in the first PCR and 
ITS-1 (internal) primers for 30 cycles of 45 s at 94 °C, 1 min at 52 °C and 45 s at 72 °C. Oligonucleotides 
used were forward ITS-1 (internal 1-5′ ): 17815′ CCTGCGGAAGGATCA3′1798 and reverse ITS-1 (inter-
nal 1-3′ ): 20R5′ GATCCGTTGTTGAAA3′5R. As an alternate second PCR, ITS-1 (internal 2) prim-
ers were used. The second PCR was carried out with 0.5 μ l of the product obtained in the first 
PCR and ITS-1 (internal 2) primers for 35 cycles of 45 s at 94 °C, 1 min at 55 °C and 45 s at 72 °C. 
Oligonucleotides used were forward ITS-1 (internal 2-5′ ): 17715´TCCGTAGGTGAACCTGCGG3′1790 
and reverse ITS-1 (internal 2-3′ ): 50R5′GCTGCGTTCATCGATGC3′30R. The third PCR was car-
ried out using the same conditions as the ITS-1 (internal 1) reaction with the primers forward 
ITS-1 (internal 3-5′ ): 16145′CTACTACCGATTGAATGGC3′1634 and reverse ITS-1 (internal 3-3′ ): 
2145′CAATTCATATTACGTATCGCA3′193. Finally, the fourth PCR assay was designed to amplify the 
ITS-2 region. The first PCR assay was carried out with 4 μ l of DNA incubated at 95 °C for 10 min fol-
lowed by 20 cycles of 45 s at 94 °C, 1 min at 52 °C and 45 s at 72 °C. Oligonucleotides used in the first 
PCR were forward ITS-2 (external 5′ ): 1525′TTTCAACAACGGATCTC3′169 and reverse ITS-2 (external 
3′ ): 8585′AGTACGGGATTCTCACCCTC3′838. The second PCR was carried out with 0.5 μ l of the product 
obtained in the first PCR and ITS-2 (internal 1) primers for 25 cycles of 45 s at 94 °C, 1 min at 55 °C, and 45 s at 
72 °C. Oligonucleotides used were forward ITS-2 (internal 1-5′ ): 2745′GCATCGATGAAGAACGCAGC3′295 
and reverse ITS-2 (internal 1-3′ ): 572R5´TCCTCCGCTTATTGATATGC3′552R.
The human β -globin gene served as a control for DNA extraction. PCR was carried out with 4 μ l 
of DNA incubated at 95 °C for 10 min and amplified with 42 cycles of 45 s at 94 °C, 1 min at 60 °C 
and 45 s at 72 °C. Oligonucleotides used were 5′GGTTGGCCAATCTACTCCCAGG 3′ and 3′ 
GCTCACTCAGTGTGGCAAAG 5′. Amplified DNA products were analysed by agarose gel electropho-
resis and stained with ethidium bromide.
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